
Rezzayo antifungal okayed as Candida auris rings alarm bells
Drug is first new echinocandin to be approved for marketing in the US in more than a decade.
Newsletters and Deep Dive digital magazine
Drug is first new echinocandin to be approved for marketing in the US in more than a decade.
But unanimous vote on biomarker validity could support accelerated approval of tofersen.
APACMed and Eversana join forces to draw up coverage frameworks applicable to APAC countries.
Delay could narrow the gap between AbbVie's product and a rival system from Mitsubishi Tanabe.
Rapid urine tests could help NHS ensure that antibiotics are used appropriately.
Editor's Picks
Newsletters and Deep Dive
digital magazine